Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that causes the loss of both muscle function and independence. DMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children).
Some 35 neuromuscular disease experts, along with biotechnology and government representatives, will meet Friday and Saturday at the Westin La Paloma here to develop a large-scale network to test potential treatments in muscular dystrophy
Despite a roller-coaster ride of ups and downs during the past 15 years, gene therapy has continued to attract many of the world's brightest scientists. They are tantalized by the enormous potential that replacing missing genes or disabling defective ones offers for curing diseases of many kinds.
Grip strength in the dominant hand and fat-free body mass (made mostly of muscle) increased when children with Duchenne muscular dystrophy (DMD) took the dietary supplement creatine at a dose of 0.1 grams per kilogram of body weight per day for four months.
The muscle supplement creatine can be safely taken by children with neuromuscular diseases, but does not improve strength or muscle mass, according to research that will be presented at the American Academy of Neurology 56th Annual Meeting in San Francisco, Calif., April 24 – May 1, 2004.
A team including MDA grantee Gordon Lynch in the Department of Physiology at the University of Melbourne in Victoria, Australia, found that a biological signaling pathway may help explain why mice with Duchenne muscular dystrophy (DMD) can regenerate their muscles much better than can humans with the same disease.
A consortium which includes Oxford researchers has won £1.6m in government funding for ground-breaking research into a possible cure for muscular dystrophy.